Moderna Therapeutics
Founded Year
2010Stage
IPO | IPOTotal Raised
$1.961BDate of IPO
12/7/2018Market Cap
51.45BStock Price
133.40About Moderna Therapeutics
Moderna Therapeutics (NASDAQ: MRNA) is a biotechnology company that is focused on drug discovery and drug development based on messenger RNA. It creates synthetic mRNA that can be injected into patients to help them create their own therapies. The company was founded in 2010 and is based in Cambridge, Massachusetts.
Missing: Moderna Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Moderna Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Moderna Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Moderna Therapeutics in 3 CB Insights research briefs, most recently on Oct 28, 2022.
Expert Collections containing Moderna Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Moderna Therapeutics is included in 4 Expert Collections, including Synthetic Biology.
Synthetic Biology
238 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Moderna Therapeutics Patents
Moderna Therapeutics has filed 144 patents.
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
9/19/2016 | 9/6/2022 | Molecular biology, RNA, Nucleotides, DNA, Gene expression | Grant |
Application Date | 9/19/2016 |
---|---|
Grant Date | 9/6/2022 |
Title | |
Related Topics | Molecular biology, RNA, Nucleotides, DNA, Gene expression |
Status | Grant |
Latest Moderna Therapeutics News
May 3, 2023
By ANNA FELICIA BAJO, GMA Integrated News Published May 3, 2023 9:19am Updated May 3, 2023 12:18pm WASHINGTON — Officials of vaccine manufacturer and Nasdaq-listed Moderna Inc. said it would establish a facility in the Philippines. In a meeting with President Ferdinand “Bongbong” Marcos Jr. on Tuesday evening (Manila time), Moderna Chief Commercial Officer Arpa Garay and Senior Vice President and General Manager Patrick Bergstedt said they are set to establish a “Shared Service Facility for Pharmacovigilance,” which will provide more employment opportunities to health professionals in the country. Garay said the Shared Service Facility for Pharmacovigilance in the Philippines would serve the entire Asia Pacific Region, noting the successful public-private partnership between the Philippine government and Moderna that they want to further explore. “We are really excited to have selected the Philippines for the third one primarily because you know the capabilities exist. We have the talent that exists, and we know that the partnership will be one that can be beneficial for both Moderna and the Philippines,” Garay said. In an emailed statement Moderna said it plans to start operations in the Philippines by the third quarter of the year, through the establishment of an Enterprise Solutions Hub in the country. The hub will provide new capabilities, service lines, and capacity to help meet the growth of its commercial and business operations in the Asia Pacific region, Moderna said. It will initially house finance, pharmacovigilance, medical, and human rights personnel, in addition to commercial-focused roles which will support its direct presence in the market, with some 40 to 50 employees in the country within the year. 'Perfect location' Bergstedt said the Philippines is the “perfect location” for their third shared service facility in the world. Once operational, it will be Moderna’s only shared service facility in Asia and the third in the world following Poland and Georgia in the United States. The facility could employ around 50 staff composed of health professionals with their shortlisted office location either in Makati or at the Bonifacio Global City in Taguig. Marcos then expressed gratitude to Moderna, saying that it will give the country advantage in healthcare. “The opportunity to build shared services in areas of interest, connecting with the scientific, academic opportunity with Moderna, the ministry of health is something that we’re very, very interested in. The most important part is that we sat down and drew the program, and say this is how we approach the problem,” Marcos said. “Those are the kind of skills that we need. With your experience in other countries, there are many lessons that we could learn that can be applied in the Philippines,” he added. — with Jon Viktor D. Cabuenas/RSJ/KBK, GMA Integrated News
Moderna Therapeutics Frequently Asked Questions (FAQ)
When was Moderna Therapeutics founded?
Moderna Therapeutics was founded in 2010.
Where is Moderna Therapeutics's headquarters?
Moderna Therapeutics's headquarters is located at 200 Technology Square, Cambridge.
What is Moderna Therapeutics's latest funding round?
Moderna Therapeutics's latest funding round is IPO.
How much did Moderna Therapeutics raise?
Moderna Therapeutics raised a total of $1.961B.
Who are the investors of Moderna Therapeutics?
Investors of Moderna Therapeutics include Merck & Co., Viking Global Investors, EDBI, Fidelity Investments, ArrowMark Partners and 18 more.
Who are Moderna Therapeutics's competitors?
Competitors of Moderna Therapeutics include Ethris and 2 more.
Compare Moderna Therapeutics to Competitors
Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.
ReCode Therapeutics is a genetic medicines company for mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. The company's lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.
HDT Bio is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. The company was founded in 2018 and is based in Seattle, Washington.
Ethris develops mRNA therapeutics with a focus on respiratory diseases and vaccines. Its RNA technology platform helps enable the discovery, design, and development of transcript therapies that assist in restoring missing functions in patients' cells and tissues. The company was founded in 2009 and is based in Planegg, Germany.
BioNTech (NASDAQ: BNTX) offers new immunotherapy solutions for cancer and other diseases. The Company focuses on the computational discovery and therapeutic drug platforms for developing biopharmaceuticals. It works with pharmaceutical collaborators, such as Genmab, Sanofi, Genentech, Genevant, Fosun Pharma, and Pfizer. The company was founded in 2008 and is based in Mainz, Germany.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.